Cost-effectiveness decision making and US public opinion

JAMA Internal Medicine

Volumn 174, Issue 1, 2014, Pages 141-143

  Botta, Michael D ^a   Blendon, Robert J ^b   Benson, John M ^b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; FEMALE; FIELD WORK; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HUMAN; LETTER; LIFE EXTENSION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC OPINION; REIMBURSEMENT; TELEPHONE INTERVIEW; UNITED STATES; VIGNETTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEALTH CARE COSTS; HEALTH POLICY; HUMANS; MALE; MIDDLE AGED; PUBLIC OPINION; UNITED STATES; YOUNG ADULT;

EID: 84892424293     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.11332     Document Type: Letter

References (6)

1. Kernick D. Beta interferon, NICE, and rationing. Br J Gen Pract. 2002;52(482):784-785.
2. Piovella M, Monés J. Since the European Medicines Agency approval of Lucentis, is the use of Avastin still justified and ethical? Ocular Surgery News Europe Asia Edition; February 2009.
3. Cimberle M. Italy approves bevacizumab for reimbursement, sparking controversy. Ocular Surgery News Europe Asia Edition; August 2007.
4. Pavlou F. Avastin to be reimbursed by the Italian authorities. http://www.oteurope.com/ophthalmologytimeseurope/content/printContentPopup.jsp? id=476054. Accessed September 10, 2013.
5. Smith R. Bowel cancer drug Avastin turned down by Nice. http://www.telegraph.co.uk/health/healthnews/7959762/Bowel-cancer-drug-Avastin- turned-down-by-Nice.html. Accessed September 10, 2013.
6. Buck AK, Herrmann K, Stargardt T., Dechow T, Krause BJ, Schreyögg J. Economic evaluationof PET and PET/CTin oncology: evidence and methodologic approaches. J Nucl Med Technol. 2010;38(1):6-17.